For decades, the medical community has grappled with a significant clinical uncertainty: Should healthy older adults, who have successfully navigated into their seventh decade without cardiovascular disease, be prescribed statins? While statins are the gold standard for secondary prevention—protecting those who have already suffered a heart attack or stroke—their role in primary prevention for the "oldest old" has remained a subject of intense debate.
That uncertainty has finally met a robust, evidence-based challenge. In a major milestone for geriatric cardiology, the STAREE (Statins for Reducing Events in the Elderly) trial has provided the first definitive evidence that primary prevention with statins offers tangible cardiovascular benefits for healthy adults aged 70 and older. The findings, presented at the European Society of Cardiology (ESC) annual meeting in Munich and simultaneously published in the New England Journal of Medicine, are poised to reshape clinical practice guidelines globally.
The Core Findings: A Shift in Cardiovascular Protection
The STAREE trial, a large-scale, randomized, pragmatic study, followed nearly 10,000 healthy, community-dwelling older adults over a median period of approximately six years. Participants were randomized in a 1:1 ratio to receive either 40 mg of atorvastatin daily or a placebo.
The primary endpoint—a composite of death from cardiovascular causes, nonfatal myocardial infarction (MI), stroke, or coronary revascularization—revealed a clear benefit for the treatment arm. Researchers observed 10.9 events per 1,000 person-years in the atorvastatin group, compared to 15.5 events per 1,000 person-years in the placebo group. This translates to a hazard ratio (HR) of 0.70, with a 95% confidence interval of 0.61–0.82.
"For the first time, we have clear evidence that primary prevention statins have a definitive place in the management of healthy older adults," said lead investigator Sophia Zoungas, MBBS, PhD, of Monash University in Melbourne, Australia.
However, the study also provided a nuanced perspective on the limitations of these drugs. While statins significantly reduced the risk of myocardial infarction and the need for coronary revascularization, they did not move the needle on "disability-free survival." When researchers looked at a combined endpoint of death from any cause, dementia, or persistent physical disability, the difference between the groups was not statistically significant (21.6 vs. 23.0 events per 1,000 person-years; HR 0.94; 95% CI 0.84–1.05).
Chronology of the STAREE Trial
The journey of the STAREE trial represents a multi-year effort to address a critical gap in medical literature.
- Study Design and Recruitment: The study recruited nearly 10,000 participants aged 70 and older living independently across Australia. The cohort was balanced by sex, with an average age of 74.7 years. Participants entered the trial with a mean LDL cholesterol of 127 mg/dL and no history of cardiovascular disease or life-limiting conditions.
- The Intervention Phase: Participants began with a 20-mg dose of atorvastatin, which was titrated to 40 mg as tolerated. The pragmatic nature of the trial was intended to mimic real-world practice, including its inherent challenges with adherence and dose adjustments.
- The Follow-Up Period: Over nearly six years, researchers tracked cardiovascular events and safety outcomes. By the end of the study, the atorvastatin group showed a significant reduction in lipid profiles, with a 48 mg/dL drop in LDL cholesterol compared to the placebo group.
- Data Analysis and Presentation: Following the completion of the follow-up, the data were analyzed to compare the efficacy of statins against the backdrop of potential side effects and the competing risks of death inherent in an aging population. The results were officially unveiled at the ESC meeting in Munich, marking a turning point in the field.
Supporting Data: Efficacy Amidst Pragmatic Challenges
A remarkable aspect of the STAREE trial is that the cardiovascular benefits were realized despite significant "real-world" hurdles. The researchers reported substantial crossovers, where participants in the placebo group eventually began taking open-label statins, and a high rate of discontinuation in the treatment arm.
At the one-year mark, 80.2% of the atorvastatin group remained on the medication. By the five-year mark, this had dropped to 55.6%. Interestingly, the most common reason for stopping the medication was not drug-induced side effects or intolerance, but rather "participant unwillingness" (15.6%), whereas only 7.2% discontinued due to adverse events.
"The effects were especially notable and are likely conservative," Dr. Zoungas and her colleagues noted in their New England Journal of Medicine manuscript. "Given the substantial percentage of participants who discontinued the trial regimen, as well as the greater use of open-label statins in the placebo group, the true preventive power of the drug is likely higher than what we have observed."
Regarding safety, the trial provided a significant degree of reassurance. Overall serious adverse events occurred at a rate of 2.7% in both the atorvastatin and placebo groups. This directly addresses one of the most common physician concerns: the fear that statins, while effective for the heart, might impose an intolerable burden of muscle pain or other systemic side effects on the elderly.
Official Responses and Clinical Implications
The medical community has received the findings with cautious optimism. For years, the American lipid guidelines had assigned a weak "Class IIb" recommendation for moderate-intensity statins in the oldest old, largely due to a lack of high-quality randomized trial data.
"What we hope to see, now that we have provided such strong evidence, are updated treatment guidelines to help clinicians make use of this new finding," Dr. Zoungas stated in a press release.
The implication for primary care physicians is a shift toward a more proactive, yet personalized, approach. The findings suggest that age alone should no longer be a reason to withhold statin therapy if a patient is otherwise healthy and motivated. However, the trialists emphasize that this does not imply a "one-size-fits-all" mandate.
"I think it’s a conversation that a person needs to have with their treating physician, weighing up the risks and benefits, and understanding whether they will be able to tolerate a statin," Zoungas explained during the ESC press conference. The nuance lies in identifying patients who are at risk of cardiovascular events versus those for whom the competing risks of mortality—such as cancer or other non-cardiovascular age-related diseases—take precedence.
Future Directions and Limitations
While STAREE is a landmark study, the researchers were transparent about its limitations. The cohort was predominantly white and English-speaking, and it excluded frail individuals and those with significant coexisting medical conditions. This means the findings may not be fully generalizable to more diverse populations or those with high levels of physical frailty.
The research landscape is far from stagnant, however. Several other high-profile studies are currently underway or recently completed, which will provide further clarity. These include:
- PREVENTABLE: A large, U.S.-based trial that is also testing atorvastatin 40 mg against a placebo in older adults, focusing on disability-free survival and cognitive outcomes.
- STREAM: A European study that has recently finished investigating the safety and feasibility of "statin deprescribing" in patients with multimorbidity, providing a counter-perspective on the long-term use of these medications.
As the global population continues to age, the question of how to best maintain healthspan—not just lifespan—is of paramount importance. Dr. Zoungas indicated that future research might investigate whether higher doses or combination therapies could provide even greater protection without compromising safety.
Ultimately, the STAREE trial has bridged a significant chasm in geriatric medicine. By proving that statins can safely and effectively reduce cardiovascular events in the over-70 population, the study has provided the missing piece of the puzzle for clinicians worldwide. As guidelines are updated to reflect this evidence, the focus will likely shift from whether to prescribe statins to how to best integrate them into the comprehensive care plans of an aging society, ensuring that patients can enjoy not only longer lives but healthier ones.
